Ross Breckenridge

We are developing an entirely novel class of orally available small molecules to address untreatable cancers. Our first drug, Ag5, aims to redefine the treatment landscape for solid tumours on both sides of the blood brain barrier by targeting the 30% of all cancers that generate high levels of Reactive Oxygen Species. This large group contains cancers driven by mutations in the KRAS gene, triple negative breast cancer and glioblastoma-all of which are urgent unmet medical needs with large potential markets. We have a deep pipeline of follow- on medicines. Our goal is to revolutionise cancer treatment for patients and their doctors.